---
title: "T&K released its performance for the first half of the year, with a net profit attributable to the parent company of 37.0848 million yuan, a year-on-year decrease of 56.75%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253830719.md"
description: "T&K released its semi-annual report for 2025, with operating revenue of 347 million yuan, a year-on-year decrease of 12.23%; net profit attributable to the parent company was 37.0848 million yuan, a year-on-year decrease of 56.75%; net profit excluding non-recurring gains and losses was 36.8806 million yuan, a year-on-year decrease of 56.30%; basic earnings per share were 0.09 yuan"
datetime: "2025-08-20T13:18:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253830719.md)
  - [en](https://longbridge.com/en/news/253830719.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253830719.md)
generator: "portal-rs"
---

# T&K released its performance for the first half of the year, with a net profit attributable to the parent company of 37.0848 million yuan, a year-on-year decrease of 56.75%

According to the Zhitong Finance APP, T&K (301263.SZ) released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 347 million yuan, a year-on-year decrease of 12.23%. The net profit attributable to shareholders of the listed company was 37.0848 million yuan, a year-on-year decrease of 56.75%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 36.8806 million yuan, a year-on-year decrease of 56.30%. The basic earnings per share were 0.09 yuan

### Related Stocks

- [301263.CN](https://longbridge.com/en/quote/301263.CN.md)

## Related News & Research

- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [CDC lifts beneficial stake in Exosens to 11.71% of capital, 13.87% of voting rights](https://longbridge.com/en/news/296499698.md)
- [ULTP: Proprietary brand sales rose 5.3% as revenues fell 3.5%, with FY27 outlook remaining cautious](https://longbridge.com/en/news/296308991.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)
- [OCC races to finalize GENIUS Act stablecoin rules by November](https://longbridge.com/en/news/296383830.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**